Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA#Italy#Orphan_Drug#Castelvecchio_Pascoli#Kedrion#Aceruloplasminemia
Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA
Kedrion's treatment for aceruloplasminemia has received Orphan Drug Designation from EMA, marking a significant advance for rare disease therapies.
third-news.com
November 27, 2025 at 10:11 AM
Kedrion's Plasma Treatment Receives Orphan Drug Designation from EMA#Italy#Orphan_Drug#Castelvecchio_Pascoli#Kedrion#Aceruloplasminemia
Kedrion's Plasma-Derived Treatment Receives Orphan Drug Designation for Rare Genetic Disorder#Italy#EMA#Castelvecchio_Pascoli#Kedrion#Aceruloplasminemia
Kedrion's Plasma-Derived Treatment Receives Orphan Drug Designation for Rare Genetic Disorder
Kedrion's innovative plasma-derived therapy has been given Orphan Drug Designation by the EMA, targeting a rare genetic condition known as Aceruloplasminemia.
third-news.com
November 27, 2025 at 10:08 AM
Kedrion's Plasma-Derived Treatment Receives Orphan Drug Designation for Rare Genetic Disorder#Italy#EMA#Castelvecchio_Pascoli#Kedrion#Aceruloplasminemia
Kedrion's Commitment to Innovation and Patient Care at IPIC 2025#Italy#Castelvecchio_Pascoli#Kedrion#Immunodeficiencies#IPIC_2025
Kedrion's Commitment to Innovation and Patient Care at IPIC 2025
Kedrion Biopharma participates in IPIC 2025 focusing on secondary immunodeficiencies. The event offers insights into cutting-edge therapeutic advancements.
third-news.com
November 17, 2025 at 10:26 AM
Kedrion's Commitment to Innovation and Patient Care at IPIC 2025#Italy#Castelvecchio_Pascoli#Kedrion#Immunodeficiencies#IPIC_2025
Kedrion Pioneers Discussion on Secondary Immunodeficiencies at IPIC 2025#Italy#Kedrion_Biopharma#Castelvecchio_Pascoli#Immunodeficiencies#IPIC_2025
Kedrion Pioneers Discussion on Secondary Immunodeficiencies at IPIC 2025
Kedrion Biopharma is leading the conversation on secondary immunodeficiencies at IPIC 2025, emphasizing patient care and innovative therapies.
third-news.com
November 7, 2025 at 5:05 PM
Kedrion Pioneers Discussion on Secondary Immunodeficiencies at IPIC 2025#Italy#Kedrion_Biopharma#Castelvecchio_Pascoli#Immunodeficiencies#IPIC_2025
Kedrion Biopharma Marks 2024 with 10% Growth and Brand Revamp#Italy#biopharmaceuticals#Kedrion_Biopharma#plasma-derived_therapies#Castelvecchio_Pascoli
Kedrion Biopharma Marks 2024 with 10% Growth and Brand Revamp
Kedrion Biopharma showcases a significant 10% growth for 2024 along with the launch of its new brand identity aimed at enhancing patient therapy access.
third-news.com
April 14, 2025 at 2:00 PM
Kedrion Biopharma Marks 2024 with 10% Growth and Brand Revamp#Italy#biopharmaceuticals#Kedrion_Biopharma#plasma-derived_therapies#Castelvecchio_Pascoli